phrykt

C4 Therapeutics, Inc. (CCCC): who owns it and who trades it

As of Nov 13, 2026, CCCC insiders reported 2 open-market sales worth $145K and no purchases in the last 12 months, with 85% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kendra Adams (CFO), with $122K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 13, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling C4 Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CCCC

147 funds and institutions reported CCCC shares worth $551M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Morgan Stanley with 8.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Morgan Stanley8.0%
Ra Capital Management, L.P.7.2%
BlackRock, Inc.7.1%
Lynx1 Capital Management LP6.6%
Squadron Capital Management LLC6.5%
Bain Capital Life Sciences Investors, LLC6.5%
JPMorgan Chase & Co4.3%
Vanguard Capital Management LLC4.0%
Citadel Advisors LLC3.8%
Goldman Sachs Group Inc3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Morgan Stanley8.87M8.02%$41.4M-2%
Ra Capital Management, L.P.8.00M7.24%$37.4MNo change
BlackRock, Inc.7.90M7.14%$36.9M+285%
Lynx1 Capital Management LP7.33M6.63%$34.2M+5%
Squadron Capital Management LLC7.20M6.51%$33.6M+220%
Bain Capital Life Sciences Investors, LLC7.17M6.49%$33.5MNo change
JPMorgan Chase & Co4.75M4.29%$20.7M–
Vanguard Capital Management LLC4.42M4.00%$20.6M+14%
Citadel Advisors LLC4.19M3.79%$19.6M+67%
Goldman Sachs Group Inc3.53M3.19%$16.5M+48%
Wasatch Advisors LP3.52M3.19%$16.5M+19%
Two Sigma Investments, LP3.47M3.14%$16.2M+14%
Soleus Capital Management, L.P.3.38M3.06%$15.8M-11%
Silverarc Capital Management, LLC3.03M2.74%$14.2M+59%
Bank of America Corp2.66M2.40%$12.4M+13%
Geode Capital Management, LLC2.52M2.28%$11.8M+165%
Ikarian Capital, LLC2.43M2.20%$11.4M–
State Street Corp2.12M1.91%$9.9M+452%
Acadian Asset Management LLC1.81M1.63%$8.4M-4%
Candriam S.C.A.1.80M1.63%$8.4M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CCCC insiders reported $0 of open-market purchases and $145K of sales. 85% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$145K
2 trades, 2 people
Sales under a 10b5-1 plan
85%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 13, 2026

Purchases and sales by month

$122K$122KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Kendra AdamsCFOSale plan45,173$2.71$122KForm 4
Jan 16, 2026Leonard ReynoChief Medical OfficerSale10,000$2.22$22.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kendra AdamsChief Financial Officer–$122KNov 12, 2026
Leonard ReynoChief Medical Officer–$22.2KJan 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CCCC short interest

Very high short interest. 35.5% of CCCC shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 119%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 46.58M CCCC shares were sold short, 35.5% of the shares outstanding, up 9.0% from the report before. At the average daily volume of 3.08M shares, buying them all back would take about 15.1 trading days (days to cover).

Shares short, % of all shares

35.5%May 15Oct 3037.9%

Days to cover

15.1May 15Oct 3025.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202646.58M35.47%+9%3.08M15.1
Oct 15, 202642.72M34.73%+6%2.52M16.9
Sep 30, 202640.40M32.84%+1%2.29M17.6
Sep 15, 202640.19M32.67%+7%1.77M22.7
Aug 31, 202637.41M30.41%+10%2.24M16.7
Aug 14, 202634.05M27.68%+12%2.44M13.9
Jul 31, 202630.43M24.73%+28%2.74M11.1
Jul 15, 202623.82M21.54%-5%3.58M6.7
Jun 30, 202625.00M22.61%+12%4.76M5.2
Jun 15, 202622.25M20.12%+3%2.34M9.5
May 29, 202621.65M19.58%+2%2.30M9.4
May 15, 202621.25M19.22%+1%3.66M5.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

C4 Therapeutics company events

C4 Therapeutics filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 25, 2026AnnouncementThe Company announced new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma ( “ RRMM ”), as well as preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of cemsidomide… Filing
  3. Aug 11, 2026ResultsReleased financial results. Filing
  4. Jun 24, 2026VoteReported shareholder vote results. Filing
  5. Jun 11, 2026AnnouncementThe Company posted on its website a poster presentation with further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma, to be presented at the European… Filing
  6. May 15, 2026LeadershipC4 Therapeutics, Inc. determined that Mark Mossler will no longer serve as the Company’s Chief Accounting Officer, effective May 15, 2026. Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. Apr 10, 2026RulesChanged its bylaws or articles. Filing
  9. Apr 9, 2026AgreementSigned an important agreement. Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Jan 14, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

C4 Therapeutics financials

Famous investors that hold CCCC

4 of the 50 well-known investors we track reported holding CCCC in their latest 13F filing. The largest position is Ken Griffin's, worth $19.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ2 20264.19M$19.6M0.0%+67%
Jim Simons · Renaissance TechnologiesQ3 20261.21M$4M0.0%+2%
Israel Englander · Millennium ManagementQ2 2026215,386$1M0.0%-85%
Steve Cohen · Point72 Asset ManagementQ2 2026173,965$812K0.0%+3%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about C4 Therapeutics, Inc. (CCCC) stock

Who owns the most CCCC stock?

The largest reported owner of C4 Therapeutics, Inc. (CCCC) is Morgan Stanley, with 8.0% of the company. In total, 147 funds and institutions reported holding CCCC at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CCCC insiders buying or selling?

In the last 12 months, CCCC insiders reported no open-market purchases and 2 sales worth $145K. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in CCCC?

As of Oct 30, 2026, 46.58M CCCC shares were sold short, 35.5% of the shares outstanding, up 9.0% from the report before. At the average daily volume of 3.08M shares, buying them all back would take about 15.1 trading days (days to cover). See the history.

Which famous investors hold CCCC?

4 of the 50 well-known investors we track reported CCCC in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $19.6M. See all holders.

Executive pay

C4 Therapeutics's chief executive was paid a total of $2.9M for the year ended Dec 31, 2025, down 37% from $4.6M the year before. In the last 12 months, C4 Therapeutics's executives and directors bought no stock on the open market and sold $145K.

Chief executive, total pay$2.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.